HOME >> MEDICINE >> NEWS
Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors

One of the nation's leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online today by JAMA because of its relevance to the recent withdrawals and warning labels on the pain-relieving drugs known as COX-2 inhibitors. The article will be published in a print edition of JAMA in early 2005.

Eric J. Topol, M.D., from the Cleveland Clinic Foundation, writes that the cardiovascular risks of the various coxib drugs were not well-studied in clinical trials. "Based on data available in 2001 for celecoxib and rofecoxib, my colleagues and I concluded: 'it is mandatory to conduct a trial specifically assessing cardiovascular risk and benefit of these agents. Until then, we urge caution in prescribing these agents to patients at risk for cardiovascular morbidity.' Unfortunately, no such trials were ever initiated and the official warnings for the coxib drugs took years to materialize."

"Importantly, providing more authority to the FDA (Food and Drug Administration) to shape and require the execution of vital trials is perhaps the most important lesson from the coxibs," Dr. Topol writes.

" legislation is needed to empower the FDA to require industry to conduct trials that are deemed necessary to ensure the safety profile of a drug. Had coxib trials been conducted five years ago in patients with established cardiovascular disease, when the benefit and risks were indeterminate, clinicians would have quickly learned the risk and potentially avoided a major cardiovascular calamity. The combination of mass promotion of a medicine with an unknown and suspect safety profile cannot be tolerated in the future. An aggressive position going forward is necessary for not only ensuring the safety of prescription medicines, but also to restore a solid foundation of public trust."


'"/>

Contact: Cole Hatcher
216-445-1991
JAMA and Archives Journals
28-Dec-2004


Page: 1

Related medicine news :

1. Specialist care gives better rate of survival
2. Special imaging study shows failing hearts are energy starved
3. Specialist available to discuss the polycystic ovary syndrome (PCOS) and patient quality of life
4. Specialized care from hospital to home improves the health of elderly with heart failure
5. Special incubators allow high-quality imaging of critically ill newborns
6. Specialists: Laparoscopy can help infertile women avoid months of unnecessary treatments
7. Issues in medical ethics: 2004 Special challenges for pediatrics
8. Specialty medical societies offer evidence-based conclusions on inhaled steroid treatment for asthma
9. American Academy of Ophthalmology announces Special Recognition Award recipients
10. Special supplement to Journal of Clinical Pharmacology features latest NIDA research on marijuana
11. Specialist mental health services required for refugees exposed to extreme trauma

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
Cached News: